

Ovid Therapeutics Inc. (OVID)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001636651

[illegible]

Letter at every rescans

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Mar 18, 2026

Ovid is a biopharmaceutical company that is dedicated to developing small molecule medicines for brain disorders with significant unmet need. These potential medicines targeting the central nervous system ("CNS") are designed to potentially halt the course of brain disease by quelling neuronal hyperexcitation and alleviating the most impactful patient symptoms. We seek to address fundamental biological targets in the brain that are implicated in neuronal hyperexcitability, such as neurotransmitters and

dysregulated ion channels.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 94.4						
Gross profitability		not computable	32.2%			one or more required annual facts are missing
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		17.2%	(6.6%)	94.4	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 23.6						
Twelve-month failure probability		0.03%	0.07%	17.8	248	2026-06-30
Altman Z double-prime		0.80	(0.31)	33.9	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		8.97x	2.96x	19.1	839	2025-12-31
Growth and financing, sleeve percentile 47.5						
Revenue growth, three-year compound		69.0%	10.0%	8.7	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		(0.9%)	2.1%	53.1	704	2025-12-31
Net share issuance, one year		85.5%	2.5%	80.9	634	2026-03-16


Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 85.5%
Short runway	cash runway is 2.5 months

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
257	Lyell Immunopharma, Inc. (LYEL)	69.2	D	dilution, degenerate inputs
258	Iovance Biotherapeutics, Inc. (IOVA)	69.5	D	dilution, short runway
259	Scienture Holdings, Inc. (SCNX)	69.7	D	fortress balance sheet
260	Rockwell Medical, Inc. (RMTI)	70.0	D	
261	Bioventus Inc. (BVS)	70.3	D	
262	Ovid Therapeutics Inc. (OVID) <	70.5	D	dilution, short runway
263	uniQure N.V. (QURE)	70.8	D	fortress balance sheet
264	Regeneron Pharmaceuticals, Inc. (REGN)	71.1	D	
265	AbCellera Biologics Inc. (ABCL)	71.4	D	
266	Cumberland Pharmaceuticals Inc. (CPIX)	71.6	D	
267	Bausch & Lomb Corp. (BLCO)	71.9	D	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	105.4%	8.0%	89
Distance from 52-week high	(20.9%)	(31.4%)	64
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(8.4%)	(1.0%)	35
Book value to price	0.46	0.28	68
Sales to price	0.02	0.31	7
Composite equity issuance, five years	108.9%	20.3%	79
Relative strength against the sector, log excess return	0.51	(0.14)	89

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	

Cash and equivalents	\$11.3M
Operating cash flow, four quarters	-\$54.8M
Months of runway	2.5
Days since last periodic filing	57 (10-Q received Aug 13, 2026)
Median daily dollar volume, 63 sessions	\$3.5M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$17.4M	2025-12-31	2026-03-18	10-K	0001628280-26-019438
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$38.3M	2025-12-31	2026-03-18	10-K	0001628280-26-019438
3	assets	us-gaap:Assets	\$150.9M	2025-12-31	2026-03-18	10-K	0001628280-26-019438
4	assets	us-gaap:Assets	\$92.2M	2024-12-31	2026-03-18	10-K	0001628280-26-019438
5	current assets	us-gaap:AssetsCurrent	\$74.4M	2025-12-31	2026-03-18	10-K	0001628280-26-019438
6	current liabilities	us-gaap:LiabilitiesCurrent	\$8.3M	2025-12-31	2026-03-18	10-K	0001628280-26-019438
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$321.7M	2025-12-31	2026-03-18	10-K	0001628280-26-019438
8	operating income	us-gaap:OperatingIncomeLoss	-\$42.4M	2025-12-31	2026-03-18	10-K	0001628280-26-019438
9	book equity	us-gaap:StockholdersEquity	\$130.7M	2025-12-31	2026-03-18	10-K	0001628280-26-019438
10	liabilities	us-gaap:Liabilities	\$20.3M	2025-12-31	2026-03-18	10-K	0001628280-26-019438
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$7.3M	2025-12-31	2026-03-18	10-K	0001628280-26-019438
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$566,000	2024-12-31	2026-03-18	10-K	0001628280-26-019438
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$392,000	2023-12-31	2025-03-11	10-K	0001628280-25-011844
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.5M	2022-12-31	2024-03-08	10-K	0001628280-24-009809
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$0	2025-12-31	2026-03-18	10-K	0001628280-26-019438
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$56.0M	2024-12-31	2026-03-18	10-K	0001628280-26-019438
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$71,000	2024-12-31	2026-03-18	10-K	0001628280-26-019438
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$45.8M	2023-12-31	2025-03-11	10-K	0001628280-25-011844
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$40,000	2023-12-31	2025-03-11	10-K	0001628280-25-011844
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$55.2M	2022-12-31	2024-03-08	10-K	0001628280-24-009809
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$1.2M	2022-12-31	2024-03-08	10-K	0001628280-24-009809
22	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$273,000	2025-12-31	2026-03-18	10-K	0001628280-26-019438
23	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$174M	2025-12-31	2026-03-18	10-K	0001628280-26-019438
24	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2025-12-31	2026-03-18	10-K	0001628280-26-019438
25	current assets	us-gaap:AssetsCurrent	\$55.9M	2024-12-31	2026-03-18	10-K	0001628280-26-019438
26	current liabilities	us-gaap:LiabilitiesCurrent	\$10.5M	2024-12-31	2026-03-18	10-K	0001628280-26-019438
27	assets	us-gaap:Assets	\$144.0M	2023-12-31	2025-03-11	10-K	0001628280-25-011844
28	assets	us-gaap:Assets	\$155.3M	2022-12-31	2024-03-08	10-K	0001628280-24-009809
29	shares outstanding	dei:EntityCommonStockSharesOutstanding	131,874,634	2026-03-16	2026-03-18	10-K	0001628280-26-019438
30	shares outstanding	dei:EntityCommonStockSharesOutstanding	71,109,514	2025-03-07	2025-04-30	10-K/A	0001628280-25-021055